H. Lundbeck A/S

Copenhagen Stock Exchange HLUN-B.CO

H. Lundbeck A/S Price to Sales Ratio (P/S) on January 14, 2025: 1.77

H. Lundbeck A/S Price to Sales Ratio (P/S) is 1.77 on January 14, 2025, a 4.69% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

H. Lundbeck A/S 52-week high Price to Sales Ratio (P/S) is 2.33 on August 27, 2024, which is 31.98% above the current Price to Sales Ratio (P/S).
H. Lundbeck A/S 52-week low Price to Sales Ratio (P/S) is 1.48 on February 08, 2024, which is -16.27% below the current Price to Sales Ratio (P/S).
H. Lundbeck A/S average Price to Sales Ratio (P/S) for the last 52 weeks is 1.85.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Copenhagen Stock Exchange: HLUN-B.CO

H. Lundbeck A/S

CEO	Mr. Charl van Zyl
IPO Date	June 10, 2022
Location	Denmark
Headquarters	Ottiliavej 9
Employees	5,800
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Key trends

Past 5 years